Free to Attend for Drug Developers, Researchers and Academics!
Drawing on a multitude of disease areas spanning neurology, cardiology, metabolic, renal, inflammatory and more, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities.
With 2 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and valuable networking opportunities, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory, payer and commercial discussions.
Improving early validation, patient selection, clinical utility demonstration and reducing diagnostic timelines is critical to closing the gap on unmet clinical need for defined patient groups.
Built exclusively for biopharma, researchers and diagnostic developers, this meeting focuses specifically on the advancement of precision medicine in rare and defined patient groups. You can join fellow discovery, translational, clinical and commercial teams all dedicated to tackling the field’s most pressing challenges to radically improve patient outcomes and quality of care.
FREE for Drug Developers, Researchers, Academics: USD 0.0
Speakers: Allison Armstrong, Senior Scientific Director, Rare Disease Programs, HemoShear, Emily McGinnis, Chief Patient Officer and Head, Taysha Gene Therapies, George Bashirians, Senior Director and Diagnostics Lead, Non-Oncology Programs, WRD Target Sciences, ESandI, Pfizer, Jana Von Hehn, Senior Director, Research and Clinical Strategy, Rett Syndrome Research Trust, Jason Bradt, Head, Rare Disease North America Medical Affairs and Director, Medical Affairs Operations, Ipsen, Johan Luthman, Executive Vice President, Research and Development, Lundbeck, Kelly George, Senior Scientist, Metabolic and Lysosomal Storage Diseases, Sanofi, Kemi Olugemo, Executive Medical Director, Neurology, Akcea Therapeutics, Kenneth Rhodes, Senior Vice President, Therapeutics Discovery, Wave Life Sciences, Krystin Meidell, Manager, Regulatory Affairs CMC Medical Devices and Combination Products, Biogen, Michael Kiebish, Chief Precision Medicine Officer, Berg Health, Michael Pratta, Principal Scientist, Translational Sciences, Incyte, Nan Doyle, RandD Patient Engagement Lead, Rare Diseases, Takeda, Paul Nioi, Senior Director, Translational Research, Alnylam Pharmaceuticals, Pranav Sharma, Founder and Chief Scientific Officer and Staff Scientist, Xosomix and Scripps Research, Priya Chockalingam,Director and Diagnostics Pathways Lead, Biogen, Shashi Ramaiah, Executive Director, Global Head of Safety Biomarkers and Translational Sciences Drug Safety RandD, Pfizer, Thomas Pisani, Director, Diagnostic Devices, Medical Device CoE, Takeda, Yossi Dagon, Principle Scientist, Biomarker Development, Goldfinch Bio
Time: 2:50 pm - 11:00 pm